205 related articles for article (PubMed ID: 31209622)
1. Two-year outcomes of single-session high-intensity focused ultrasound (HIFU) treatment in persistent or relapsed Graves' disease.
Lang BH; Woo YC; Chiu KW
Eur Radiol; 2019 Dec; 29(12):6690-6698. PubMed ID: 31209622
[TBL] [Abstract][Full Text] [Related]
2. Single-Session High-Intensity Focused Ultrasound Treatment for Persistent or Relapsed Graves Disease: Preliminary Experience in a Prospective Study.
Lang BH; Woo YC; Wong IY; Chiu KW
Radiology; 2017 Dec; 285(3):1011-1022. PubMed ID: 28727542
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of single-session radiofrequency ablation (RFA) in rendering euthyroidism for persistent/relapsed Graves' disease, a pilot study.
Fung MHM; Lang BHH
Eur Radiol; 2023 Sep; 33(9):6534-6544. PubMed ID: 37036479
[TBL] [Abstract][Full Text] [Related]
4. High-intensity focused ablation (HIFU) of single benign thyroid nodule rarely alters underlying thyroid function.
Lang BHH; Woo YC; Chiu KW
Int J Hyperthermia; 2017 Dec; 33(8):875-881. PubMed ID: 28540804
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
Maugendre D; Massart C
Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
[TBL] [Abstract][Full Text] [Related]
6. The two-year results of using radiofrequency ablation as a novel treatment for persistent or relapsed Graves' disease, a prospective study.
Fung MHM; Luk Y; Yuen KK; Lang BHH
Thyroid; 2024 Jun; ():. PubMed ID: 38836419
[TBL] [Abstract][Full Text] [Related]
7. Two sequential applications of high-intensity focused ultrasound (HIFU) ablation for large benign thyroid nodules.
Lang BHH; Woo YC; Chiu KW
Eur Radiol; 2019 Jul; 29(7):3626-3634. PubMed ID: 30778718
[TBL] [Abstract][Full Text] [Related]
8. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study.
Glinoer D; de Nayer P; Bex M;
Eur J Endocrinol; 2001 May; 144(5):475-83. PubMed ID: 11331213
[TBL] [Abstract][Full Text] [Related]
9. Vocal cord paresis following single-session high intensity focused ablation (HIFU) treatment of benign thyroid nodules: incidence and risk factors.
Lang BHH; Woo YC; Chiu KW
Int J Hyperthermia; 2017 Dec; 33(8):888-894. PubMed ID: 28540836
[TBL] [Abstract][Full Text] [Related]
10. Identifying predictive factors for efficacy in high intensity focused ultrasound (HIFU) ablation of benign thyroid nodules - a retrospective analysis.
Lang BHH; Woo YC; Chiu KW
Int J Hyperthermia; 2020; 37(1):324-331. PubMed ID: 32253953
[No Abstract] [Full Text] [Related]
11. The Role of Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4) Gene, Thyroid Stimulating Hormone Receptor (TSHR) Gene and Regulatory T-cells as Risk Factors for Relapse in Patients with Graves Disease.
Eliana F; Suwondo P; Asmarinah A; Harahap A; Djauzi S; Prihartono J; Pemayun TGD
Acta Med Indones; 2017 Jul; 49(3):195-204. PubMed ID: 29093229
[TBL] [Abstract][Full Text] [Related]
12. Sequential high intensity focused ultrasound (HIFU) ablation in the treatment of benign multinodular goitre: an observational retrospective study.
Lang BHH; Woo YC; Chiu KW
Eur Radiol; 2018 Aug; 28(8):3237-3244. PubMed ID: 29556769
[TBL] [Abstract][Full Text] [Related]
13. Significance of hyperechoic marks observed during high-intensity focused ultrasound (HIFU) ablation of benign thyroid nodules.
Lang BHH; Woo YC; Chiu KW
Eur Radiol; 2018 Jun; 28(6):2675-2681. PubMed ID: 29313120
[TBL] [Abstract][Full Text] [Related]
14. Thyroid hypoechogenicity after methimazole withdrawal in Graves' disease: a useful index for predicting recurrence?
Zingrillo M; D'Aloiso L; Ghiggi MR; Di Cerbo A; Chiodini I; Torlontano M; Liuzzi A
Clin Endocrinol (Oxf); 1996 Aug; 45(2):201-6. PubMed ID: 8881453
[TBL] [Abstract][Full Text] [Related]
15. Two-year efficacy of single-session high-intensity focused ultrasound (HIFU) ablation of benign thyroid nodules.
Lang BHH; Woo YC; Chiu KW
Eur Radiol; 2019 Jan; 29(1):93-101. PubMed ID: 29922925
[TBL] [Abstract][Full Text] [Related]
16. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
17. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of HIFU for the treatment of benign thyroid nodules: a systematic review and meta-analysis.
Fan KY; Loh EW; Tam KW
Eur Radiol; 2024 Apr; 34(4):2310-2322. PubMed ID: 37792080
[TBL] [Abstract][Full Text] [Related]
19. High intensity focused ultrasound (HIFU) ablation of benign thyroid nodule is safe and efficacious in patients who continue taking an anti-coagulation or anti-platelet agent in the treatment period.
Lang BH; Woo YC; Chiu KW
Int J Hyperthermia; 2019; 36(1):186-190. PubMed ID: 30556448
[TBL] [Abstract][Full Text] [Related]
20. NIS mRNA expression level in resected thyroid tissue as a marker of postoperative hypothyroidism after subtotal thyroidectomy in patients with Graves' disease.
Goto A; Uchino S; Noguchi S; Wakiya S; Watanabe Y; Murakami T; Matsuura B; Onji M
Endocr J; 2008 Mar; 55(1):73-81. PubMed ID: 18187871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
